171 related articles for article (PubMed ID: 33372544)
1. Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa.
Siddiqui F; Antic D; Tafur A; Bontekoe E; Hoppensteadt D; Gerotziafas G; Elalamy I; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620983466. PubMed ID: 33372544
[TBL] [Abstract][Full Text] [Related]
2. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
[TBL] [Abstract][Full Text] [Related]
3. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
Siddiqui F; Tafur A; Bontekoe E; Iqbal O; Jeske W; Mehrotra S; Hoppensteadt D; Ramacciotti E; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029619895120. PubMed ID: 31914798
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ
Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866
[TBL] [Abstract][Full Text] [Related]
5. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
6. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
7. Andexanet Alfa, the Possible Alternative to Protamine for Reversal of Unfractionated Heparin.
Maneno JN; Ness GL
Ann Pharmacother; 2021 Feb; 55(2):261-264. PubMed ID: 32667214
[TBL] [Abstract][Full Text] [Related]
8. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
[TBL] [Abstract][Full Text] [Related]
9. Andexanet alfa for the treatment of hemorrhage.
Cervi A; Crowther M
Expert Rev Hematol; 2018 Nov; 11(11):847-855. PubMed ID: 30296870
[TBL] [Abstract][Full Text] [Related]
10. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system.
Furugohri T; Sugiyama N; Morishima Y; Shibano T
Thromb Haemost; 2011 Dec; 106(6):1076-83. PubMed ID: 22012070
[TBL] [Abstract][Full Text] [Related]
12. Andexanet Alfa: First Global Approval.
Heo YA
Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311
[TBL] [Abstract][Full Text] [Related]
13. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
14. Transient or extended reversal of apixaban anticoagulation by andexanet alfa is equally effective in a porcine polytrauma model.
Grottke O; Braunschweig T; Rossaint R; Akman N; Leeds JM; Conley PB; Honickel M
Br J Anaesth; 2019 Aug; 123(2):186-195. PubMed ID: 31202564
[TBL] [Abstract][Full Text] [Related]
15. Early thrombin formation capacity in trauma patients and association with venous thromboembolism.
Voils SA; Lemon SJ; Jordan J; Riley P; Frye R
Thromb Res; 2016 Nov; 147():13-15. PubMed ID: 27664391
[TBL] [Abstract][Full Text] [Related]
16. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
[TBL] [Abstract][Full Text] [Related]
17. Is It Truly "Alpha"? Incidence of Thrombotic Events With Andexanet Alfa at a Single Academic Medical Center.
Parsels KA; Seabury RW; Darko W; Probst LA; Cwikla GM; Miller CD
Ann Emerg Med; 2020 May; 75(5):675-676. PubMed ID: 32336435
[No Abstract] [Full Text] [Related]
18. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
19. Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center.
Stevens VM; Trujillo T; Mueller SW; MacLaren R; Reynolds PM; Kiser TH
Clin Appl Thromb Hemost; 2019; 25():1076029619896619. PubMed ID: 31876159
[TBL] [Abstract][Full Text] [Related]
20. FACTORS ASSOCIATED WITH INCREASED RED BLOOD CELLS TRANSFUSION REQUIREMENTS IN PATIENTS WITH HODGKIN AND NON-HODGKIN LYMPHOMA.
Ali S; Ali M; Badar F; Basit A; Hameed A
J Ayub Med Coll Abbottabad; 2015; 27(1):70-3. PubMed ID: 26182741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
